Allopurinol for newborns needing heart surgery with bypass
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Injuries & trauma clinical trials.
This trial tests whether the medicine allopurinol can protect the brain and heart in newborns with serious congenital heart disease who need heart surgery soon after birth. It may help reduce injury during and around surgery that uses a heart-lung machine (cardiopulmonary bypass).
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must have a confirmed diagnosis of critical congenital heart disease (CCHD).
- Your baby is expected to need heart surgery using a heart-lung machine (cardiopulmonary bypass) within the first 4 weeks of life.
- Both parents must be able to provide consent for the study.
- Your baby must be at least 36 weeks gestational age and weigh at least 2000 grams at birth.
- The study team must be able to enroll your baby before delivery (if diagnosed before birth) or within 24 hours before surgery (if diagnosed after birth).
- The surgery must specifically require the heart-lung machine, and care must not be comfort-care-only.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving nitric oxide during heart-lung bypass surgery can help protect a baby’s brain and kidneys. If you qualify, the study team will check outcomes after surgery to see if benefits happen compared with usual care.
This trial tests a coordinated treatment plan for newborns with critical congenital heart disease, starting before birth and continuing after delivery. It aims to improve outcomes for babies who need two-ventricle repair surgery.
This Phase 3 study tests whether not giving nitric oxide during heart-lung bypass in newborns helps reduce the risk of acute kidney injury. It focuses on newborns having heart surgery for congenital heart disease.
This trial studies patterns in immune cells (neutrophils) in very young children who undergo heart surgery using a heart-lung machine. The goal is to better understand and potentially reduce lung injury after surgery.
This trial tests whether giving methylprednisolone (a steroid medicine) can lower the body’s inflammatory response in children during the first day after congenital open-heart surgery. It may help reduce harmful inflammation and improve recovery for some children undergoing their first surgery.
This trial tests new surgical strategies for newborns with certain complex heart conditions. It aims to see which techniques lead to better recovery and quality of life in the first year after surgery.
Hear when a new Congenital Heart Disease in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.